Brian R. Mueller joined BioMarin in December 2002 and currently serves as our Chief Financial Officer. In his role, he is responsible for managing all Finance and Information Management teams. Prior to this, he served as our Senior Vice President, Finance and Chief Accounting Officer and as our Group Vice President, Corporate Controller.
Before joining BioMarin, Mr. Mueller was a senior manager in the audit practice at KPMG. He joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm’s audit and business advisory services practice.
Mr. Mueller received a B.S. in accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants. From June 2014 to May 2020, he was a member of the board of directors of Anthera Pharmaceuticals, Inc., a previously public biopharmaceutical company, where he also served as Chairman of the Audit Committee. Mr. Mueller currently serves as executive Leader Liaison of the BioMarin Asian Pacific Islander Coalition (APIC) Employee Resource Group.
We maximize the impact of genetic innovation to develop transformative therapies.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
View Now Our Pipeline ⌃